In its 2021 strategy report, the Global Initiative for Chronic Obstructive Lung Disease states: “we no longer refer to asthma-COPD overlap (ACO), instead we emphasize that asthma and COPD are different disorders, although they may […] coexist in an individual patient. If a concurrent diagnosis of asthma is suspected, pharmacotherapy should primarily follow asthma guidelines, but pharmacological and non-pharmacological approaches may also be needed for their COPD.” What does this mean for the treating physician? In this review, we explore the implications of this new guidance on treating patients with chronic obstructive pulmonary disease, arguing for a personalized approach to treatment.
CITATION STYLE
Roman-Rodriguez, M., & Kaplan, A. (2021). Gold 2021 strategy report: Implications for asthma–copd overlap. International Journal of COPD, 16, 1709–1715. https://doi.org/10.2147/COPD.S300902
Mendeley helps you to discover research relevant for your work.